Abstract
Randomized trials of GnRH agonist (GnRHa) with chemotherapy (CHEM) to preserve ovarian function in premenopausal women with breast cancer (BC) reported conflicting results. Several trials included women on Tamoxifen for treatment of hormone receptor (HR) positive BC, which may confound the results as Tamofixen is associated with amenorrhea. We performed a systematic review and meta-analysis analyzing the rate of return of menses in women after CHEM for HR negative BC with or without GnRHa.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
